PT  - JOURNAL ARTICLE
AU  - Lucas Pires Guarnier
AU  - Lincoln Gozzi Moro
AU  - Francislaine Aparecida dos Reis Lívero
AU  - Carolina Arruda de Faria
AU  - Mauricio Fogaça Azevedo
AU  - Beatriz Pizoni Roma
AU  - Edilson Rodrigues Albuquerque
AU  - Maria José Malagutti-Ferreira
AU  - Alessandra Gomes Duarte Rodrigues
AU  - Adelson Alves da Silva
AU  - Eliseo Joji Sekiya
AU  - João Tadeu Ribeiro-Paes
TI  - Regenerative and translational medicine in COPD: hype and hope
AID  - 10.1183/16000617.0223-2022
DP  - 2023 Sep 30
TA  - European Respiratory Review
PG  - 220223
VI  - 32
IP  - 169
4099  - http://err.ersjournals.com/content/32/169/220223.short
4100  - http://err.ersjournals.com/content/32/169/220223.full
SO  - EUROPEAN RESPIRATORY REVIEW2023 Sep 30; 32
AB  - COPD is a common, preventable and usually progressive disease associated with an enhanced chronic inflammatory response in the airways and lung, generally caused by exposure to noxious particles and gases. It is a treatable disease characterised by persistent respiratory symptoms and airflow limitation due to abnormalities in the airways and/or alveoli. COPD is currently the third leading cause of death worldwide, representing a serious public health problem and a high social and economic burden. Despite significant advances, effective clinical treatments have not yet been achieved. In this scenario, cell-based therapies have emerged as potentially promising therapeutic approaches. However, there are only a few published studies of cell-based therapies in human patients with COPD and a small number of ongoing clinical trials registered on clinicaltrials.gov. Despite the advances and interesting results, numerous doubts and questions remain about efficacy, mechanisms of action, culture conditions, doses, timing, route of administration and conditions related to homing and engraftment of the infused cells. This article presents the state of the art of cell-based therapy in COPD. Clinical trials that have already been completed and with published results are discussed in detail. We also discuss the questions that remain unanswered about cell-based regenerative and translational medicine for COPD.This review describes the current state of the art of cell-based, regenerative and translational medicine in COPD, presenting the clinical trials already completed and with published results. https://bit.ly/3P08Bmq